The global IgA nephropathy market is set for remarkable growth over the next decade. In 2023, the market is projected to reach a value of USD 41.24 billion and is expected to double by 2033, attaining a valuation of USD 85 billion. This growth corresponds to a compound annual growth rate (CAGR) of 7.5% during the forecast period from 2023 to 2033.
The expansion of the IgA nephropathy market is primarily driven by the increasing prevalence of kidney diseases across various age groups. Advances in diagnostics and treatment options, along with rising awareness of kidney health, are further contributing to market growth.
In the historical period from 2017 to 2022, the market registered a CAGR of 4.8%, reflecting steady progress in the field. However, the forecasted growth is expected to accelerate due to an enhanced focus on research and development, the introduction of novel therapies, and increased healthcare access in both developed and emerging regions.
The robust growth in the IgA nephropathy market is primarily driven by the increasing prevalence of kidney diseases across various age groups. This rise in incidence highlights the growing need for advanced treatments and diagnostic solutions for IgA nephropathy, a condition that affects kidney function and requires effective management strategies.
The market’s expansion reflects a significant acceleration from the historical CAGR of 4.8% registered between 2017 and 2022. This upward shift indicates heightened awareness, advancements in research, and innovations in treatment options that are contributing to improved patient outcomes and driving market growth.
The COVID-19 pandemic has been associated with increase in hospitalization and infection hotspots around the country. There were at least three separate waves of COVID-19 around the world by June 2021 that put a significant strain on hospital resources, especially labor and availability of dialysis equipment & supplies.
In addition, the COVID-19 pandemic has affected healthcare services for renal disease patients. Social distancing and lockdown were mandate norms, globally, leading to temporary closure of other medical services. The diagnosis of several renal diseases deferred during the pandemic due to suspension of non-urgent visits and testing services.
On the other hand, increasing awareness regarding IgA nephropathy is expected to create lucrative opportunities for the market growth. For instance, In the U.S., an estimated 37 million adults have kidney disease. Major risk factors for the disease are high blood pressure and diabetes as well as heart disease, obesity, & family history of kidney disease. In addition, North America and Asia Pacific are two major regions contributing to the IgA nephropathy market.
Key Takeaways from the Market Study
- IgA Nephropathy market to garner US$ 85 Billion by the end of 2033.
- IgA Nephropathy market to register a positive CAGR of 7.5% in the forecast period 2023-2033
- By end user, the hospital’s segment is expected to hold 40% of the market share in 2023 for IgA nephropathy market.
- By diagnosis, the urine tests segment is projected to witness significant a CAGR of 7.5% during the forecast years.
- North America is expected to possess 40% market share for IgA nephropathy market in 2023.
- Asia Pacific is expected to hold 35% market share for IgA nephropathy market share in 2023.
“Growing prevalence of kidney related problems along with research and development for manufacturing medication is favoring the growth of IgA nephropathy market” states a FMI analyst
Competitive Landscape
- In June 2021, Novartis Pharmaceuticals announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN).
- Chinook Therapeutics, Inc, a key player in the IgA nephropathy market is focusing on diagnosing the causes of the ailment and offering customized and specific treatments based on the same.
Key Companies Profiled:
- Calliditas Therapeutics AB
- Travere Therapeutics, Inc.
- Omeros Corporation
- Novartis Pharmaceuticals
- Chinook Therapeutics, Inc.
- Vera Therapeutics, Inc.
- Otsuka Pharmaceutical
- Alembic Pharmaceuticals Limited
- Teva Pharmaceutical Industries Ltd.
- Johnson & Johnson Private Limited
A Old Full Report Analysis Click Here
Key Segments Profiled in the IgA Nephropathy Market Survey
Diagnosis:
- Iothalamate Clearance Test
- Kidney Biopsy
- Blood Tests
- Urine Tests
Diseases Type:
- Primary IgA Nephropathy
- Secondary IgA Nephropathy
Systems:
- Hematuria
- Proteinuria
- Edema
- Others
Population Type:
- Pediatrics
- Adults
Route of Administration:
- Oral
- Parenteral
- Others
Treatment:
- Medication
- Statin therapy
- Omega-3 fatty acids
- Angiotensin-converting enzyme (ACE) inhibitors
- Angiotensin receptor blockers (ARBs)
- Diuretics
- Immunosuppressants
- Kidney Transplantation
- Others
End Users:
- Hospitals
- Specialty Clinics
- Homecare
- Others
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
